1-BOC-4-(4-溴苯甲酰)哌啶 | 439811-37-7

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-BOC-4-(4-溴苯甲酰)哌啶
• 中文别名: 1-BOC-4-(4-溴苯甲酰基)哌啶
• 英文名称: tert-butyl 4-(4-bromobenzoyl)piperidine-1-carboxylate
• 英文别名: 1-Boc-4-(4-Bromobenzoyl)piperidine
• CAS: 439811-37-7
• 化学式: C₁₇H₂₂BrNO₃
• 分子量: 368.271
• InChiKey: CJXZBFPDZDHCJT-UHFFFAOYSA-N

物化性质

• 沸点：
  452.3±40.0 °C(Predicted)
• 密度：
  1.325±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8℃

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Boc-4-(4-bromo-benzoyl)-piperidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Boc-4-(4-bromo-benzoyl)-piperidine
CAS number: 439811-37-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C17H22BrNO3
Molecular weight: 368.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-BOC-4-(4-溴苯甲酰)哌啶 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 4-[(4-bromophenyl)hydroxymethyl]piperidine-1-carboxylic acid t-butyl ester
  参考文献：
  名称：

  2-Substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

  摘要：

  本发明公开了以下式I的化合物 其中Ar、Y、m、n、R1和R4在此有定义，所述化合物是新型黑素浓缩激素（MCH）拮抗剂，以及制备这种化合物的方法。在另一实施例中，本发明公开了包含这种MCH拮抗剂的药物组合物，以及使用它们治疗肥胖、代谢紊乱、食欲紊乱（如过度进食）和糖尿病的方法。

  公开号：

  US20050054628A1
• 作为产物：
  描述：

  N-叔丁氧羰基-4-哌啶酮 在 caesium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 21.0h， 生成 1-BOC-4-(4-溴苯甲酰)哌啶
  参考文献：
  名称：

  通过甲酰基CH键插入由甲苯磺酰and和芳香醛制备不对称酮

  摘要：

  通过将重氮化合物插入醛的甲酰基C–H键来制备酮是一种有吸引力的方法，但是结构多样化的重氮化合物的使用受到制备和安全性问题的阻碍。报道了一种由台式稳定的甲苯磺酰hydr和芳基醛合成不对称酮的简便方法。该过程可以在一个母体羰基化合物的罐中进行，只需要一种碱，而无需额外的促进剂。

  DOI：

  10.1021/ol5011714

文献信息

• [EN] BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES BICYCLIQUES À TITRE DE MODULATEURS DE MNK1 ET MNK2 ET LEURS UTILISATIONS
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2013147711A1

  公开（公告）日：2013-10-03

  The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.

  本发明涉及某些化合物（例如咪唑吡嗪、咪唑吡啶、咪唑吡嗪和咪唑嘧啶化合物），这些化合物作为MAP激酶相互作用激酶MNK2a、MNK2b、MNK1a和MNK1b的抑制剂。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物制备用于预防和治疗疾病（例如增生性疾病（例如癌症）、炎症性疾病、阿尔茨海默病）的药物的用途，以及治疗这些疾病的方法。
• BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF
  申请人：Agency for Science, Technology and Research

  公开号：US20140371199A1

  公开（公告）日：2014-12-18

  The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.

  本发明涉及某些化合物（例如咪唑吡嗪、咪唑吡啶、咪唑吡嗪和咪唑嘧啶化合物），这些化合物作为MAP激酶相互作用激酶MNK2a、MNK2b、MNK1a和MNK1b的抑制剂。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物制备用于预防和治疗疾病（例如增生性疾病（例如癌症）、炎症性疾病、阿尔茨海默病）的药物的用途，以及治疗这些疾病的方法。
• [EN] 1,4-DICARBONYL-PIPERIDYL DERIVATIVES<br/>[FR] DÉRIVÉS DE 1,4-DICARBONYLE-PIPÉRIDYLE
  申请人：MERCK PATENT GMBH

  公开号：WO2017076484A1

  公开（公告）日：2017-05-11

  Compounds of the formula I in which Z, W, Q, R and Y have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

  式I中Z、W、Q、R和Y具有权利要求1中指示的含义的化合物是坦克酶的抑制剂，可用于治疗癌症、心血管疾病、中枢神经系统损伤和不同形式的炎症等疾病。
• [EN] MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS<br/>[FR] INHIBITEURS MITOCHONDRIALES POUR LE TRAITEMENT DE TROUBLES PROLIFÉRATIFS
  申请人：BASILEA PHARM INT AG

  公开号：WO2018002220A1

  公开（公告）日：2018-01-04

  The invention provides compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof (I) wherein ring A represents group A-I or A- II (A-I, A-II) A1, A2, A3, A4 represent independently C(R4aa) or N, wherein no more than one of A1, A2, A3, and A4 represents N; A5 represents C(R4b) or N; B1, B2, B3 and B4 represent independently C(R3) or N, wherein no more than two of B1, B2, B3 and B4 represent N; n is 1 or 2; and R1, R2, R3, R4a and R4aa and R4b are as defined in the claims, as well as methods of using the compounds to treat proliferation diseases, in particular cancer.

  该发明提供了式I的化合物或其药用可接受的盐、溶剂化合物或水合物(I)，其中环A代表A-I或A-II组（A-I，A-II），A1、A2、A3、A4独立地代表C(R4aa)或N，其中A1、A2、A3和A4中最多有一个代表N；A5代表C(R4b)或N；B1、B2、B3和B4独立地代表C(R3)或N，其中B1、B2、B3和B4中最多有两个代表N；n为1或2；以及R1、R2、R3、R4a和R4aa以及R4b如索权中所定义的，以及使用这些化合物治疗增殖性疾病，特别是癌症的方法。
• 2-Substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
  申请人：Wu Wen-Lian

  公开号：US20050049269A1

  公开（公告）日：2005-03-03

  The present invention discloses compounds of formula I wherein Ar, X, R 1 and R 11 are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

  本发明揭示了具有以下结构的化合物（I）其中Ar、X、R1和R11如下定义，所述化合物是新型黑素浓缩激素（MCH）拮抗剂，以及制备此类化合物的方法。在另一实施方案中，本发明揭示了包含这种MCH拮抗剂的药物组合物，以及使用它们治疗肥胖、代谢紊乱、食欲紊乱（如过食症）和糖尿病的方法。